Partial
Needs Label Review
Patient Risk:
Moderate
Summary
Several safety-related claims about liver enzyme elevations and liver risk are not supported by the provided FDA label excerpts, and one claim implies non-contradiction/monitoring guidance that is not present. Other general claims (indication class, IL-17A mechanism, injection administration) are not verifiable from the provided label excerpts.
Category Scores
Accurate Statements
COSENTYX is administered via injection.
Not directly evidenced in provided label excerpts. However, provided text states injection formulations for subcutaneous and intravenous use.
Unsupported Statements
Cosentyx (secukinumab) is a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis.
No FDA label excerpts provided in the prompt include indications/label indication language.
Cosentyx works by blocking interleukin-17A (IL-17A).
No pharmacology/mechanism language regarding IL-17A was included in the provided label excerpts.
In a study of patients with liver disease, those who received Cosentyx experienced a higher rate of liver enzyme elevations compared with those without liver disease.
No liver disease/liver enzyme elevation study details are present in the supplied label excerpts.
In the study, liver enzyme elevations in patients with liver disease receiving Cosentyx were generally mild and reversible.
No such severity/reversibility details are present in the supplied label excerpts.
Liver enzyme elevations were reported in 3.4% of patients receiving Cosentyx in clinical trials.
No numeric frequency for liver enzyme elevations is present in the supplied label excerpts.
In most cases, Cosentyx-associated liver enzyme elevations were mild and did not require treatment discontinuation.
No label excerpt in the prompt provides guidance or outcomes specific to liver enzyme elevations and discontinuation.
In a study of patients with liver disease, those who received Cosentyx had a higher risk of liver enzyme elevations and liver damage compared with those without liver disease.
No liver disease/liver damage information is present in the supplied label excerpts.
Cosentyx may not be contraindicated in liver patients.
The provided label contraindications only specify serious hypersensitivity; there is no statement about liver patients being or not being contraindicated.
Healthcare providers should monitor liver enzymes in patients with liver disease who receive Cosentyx.
No liver enzyme monitoring recommendation is present in the supplied label excerpts.
Dose adjustment or treatment discontinuation should be considered if liver enzyme elevations occur in liver patients receiving Cosentyx.
No liver enzyme elevation–based dose adjustment/discontinuation guidance is present in the supplied label excerpts.
Patients with liver disease who are likely to benefit from Cosentyx should be carefully selected.
No liver-disease-specific patient selection language is present in the supplied label excerpts.
Liver enzyme elevations are a potential side effect of Cosentyx.
No adverse reaction statement regarding liver enzyme elevations is included in the supplied label excerpts.
Liver damage is a potential risk in liver patients receiving Cosentyx.
No liver damage risk statement is included in the supplied label excerpts.
Contradictions
Low
AI Statement
Cosentyx may not be contraindicated in liver patients.
Label Reference
Label contraindications (Section 4) only list hypersensitivity to secukinumab or excipients; the prompt-provided excerpts do not include any liver-related contraindication. This claim is therefore not supported, but it is also not directly contradicted by the provided label excerpts.
Important Omissions
For the liver-related monitoring/dose adjustment/discontinuation claims, the label excerpts provided contain no liver-specific warnings, precautions, adverse reactions, or monitoring instructions (e.g., for transaminases/liver enzymes).
Importance:
Moderate
No contraindication language was provided regarding liver disease in the excerpts; therefore any assertion about liver contraindications or lack thereof cannot be grounded in the provided label text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety claims about liver disease risk, incidence, reversibility, monitoring, and discontinuation are not supported by the supplied FDA label excerpts; relying on unsupported liver-specific guidance could misinform risk management.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Label Review
Primary Issue
Major portions of the response introduce liver-disease-specific findings (incidence, severity, reversibility, liver damage, and monitoring/discontinuation recommendations) that are absent from the provided FDA label excerpts.
Suggested Improvement
Remove or rewrite liver-related claims unless the exact FDA label sections supporting them are provided (e.g., adverse reactions table, warnings/precautions subsection, or clinical study section including liver parameters). For indication and IL-17A mechanism claims, provide label excerpts from relevant sections (Indications/Clinical Pharmacology) to verify support.